radiation oncologist, innovator, clinical trialist, father, GI oncology @WashURadOnc
Joined October 2018
- Tweets 846
- Following 332
- Followers 1,067
- Likes 3,382
90 Photos and videos
Jun 8
Thank you @NiuSanford ! Congrats to the @WashUMedRadOnc team for providing these additional data to guide treatment for this very challenging clinical scenario.
May 24
SBRT (50Gy/5fx, MR adaptive) in locally recurrent PDAC.
N=46 (7 w prior RT). 1 year LC 73%, median OS 19 mo.
Ablative RT = feasible, safe in locally recurrent setting & can confer long term dz control.
Great to see this data published - congrats @adapthyun & team! @OncoAlert
2
8
1,507
Hyun Kim retweeted
Feb 18
Great talk at #MRPTS26 on managing RPT emergencies by Dr. Hyun Kim @adapthyun with a call/need for RadOnc and RPT physicians to own toxicities related to the RPTs they prescribe/administer. @cityofhope
1
3
16
942
Hyun Kim retweeted
@adapthyun of @COH_RadOnc presenting on infusion troubleshooting and radiation safety challenges with RPT. @ASTRO_org #MRPTS26
3
7
671
Hyun Kim retweeted
7
14
1,507
Hyun Kim retweeted
Feb 6
What better way to catch up with my GI rad onc friends and colleagues than at a Disney-themed restaurant, sparkly cake and all ✨ 🍰#ACRO2026 @LeilaTchelebi @adapthyun @ldawsonmd
1
1
21
1,223
Hyun Kim retweeted
Jan 12
Gathering with friends and colleagues not only keeps us going, but accelerates progress by developing and strengthening collaborations. #radonc happy hour @ASCO #GI26 @NiuSanford @alexhotca @radoncbme @ldawsonmd @lauren_henke
1
6
45
2,551
30 Nov 2025
Appreciate this fantastic opportunity! (Has been a minute since I signed onto twitter/x so sorry for the very delayed response). @COH_RadOnc and @TeWilliamsMD has been nothing short of stellar in their welcome.
6 Nov 2025
We’re thrilled to welcome @adapthyun to @COH_RadOnc! Dr. Hyun Kim is an internationally-recognized thought leader in GI cancer, adaptive radiation therapy & radiopharmaceuticals, and will lead our GI RadOnc & #theranostics programs. #radonc @cityofhope @NRGonc @ASTRO_org
1
6
396
Hyun Kim retweeted
29 Sep 2025
Our final speaker for the KOSRO-KASTRO session is Dr @jihyunRadOnc who will provide the latest evidence and advancements for treating refractory ventricular tachycardia. See you tomorrow 8am Room 314!
3
9
880
29 Sep 2025
Thanks @MikeChuongMD @sueyom! It was a privilege to work under your leadership. @IJROBP
Now time to change my email address before the reviewer invites start coming in 😁
29 Sep 2025
🤩 What a truly amazing group of human beings!!
So sorry to miss this as I was giving a talk at #ASTRO25
Excited to announce our new @IJROBP GI associate editors @LCUBLD @AitkenKatharine 🙌
Much gratitude to @adapthyun & Andrzej Wojcieszynski who are rotating off 🙏
1
14
1,647
Hyun Kim retweeted
29 Sep 2025
NOM short course ! Locally advanced after TNT and 25-30 in 5 to tumor and 30-35 to sidewall nodes had a CCR had a 72 percent CCR rate 🔥
Boost to primary did not lead to better CCR - perhaps while we know there is a dose response (OPERA trial) for locally advanced disease modern systemic helps considerably. Need to see the results of the German AIO trial - congrats to @adapthyun and the whole team 👏🏼👏🏼
6 Sep 2024
NOM-ERA (clinicaltrials.gov/study/NCT…) accrual and treatment complete! Look forward to data presented in 2025! @AnkerUVMRadOnc
15
37
6,454
Hyun Kim retweeted
27 Sep 2025
NOM-ERA results just dropped! 🔥 #ASTRO25
Awesome work @adapthyun et al!
Wondering if those who got the optional 30 Gy × 5 primary tumor boost had larger tumors or more adverse features since cCR and TME-free survival looked similar overall.
sciencedirect.com/science/ar…
12 Sep 2024
Patients deserve options, including shorter radiation courses. Agree 5-6 weeks of RT has best published rates of avoiding rectal cancer surgery so far, but all that time is hard on pts. NOM-ERA’s 1 wk of RT with boost was VERY popular with @UVMcancercenter pts. Eager for results!
1
9
19
14,783
Hyun Kim retweeted
28 Sep 2025
Yup, I wouldn’t give up on SCRT so easily to go back to CRT without conclusive data. Keep going @adapthyun. I will also be excited to see what PULSAR with gross dz boost can do from @NiuSanford! Looking forward to seeing head to head of just 5x5 vs CRT.
1
6
333
Hyun Kim retweeted
27 Sep 2025
And the plot thickens for short course RT in rectal cancer!
72% cCR & 57% 2-year TME free survival via 4 cycles FOLFOX/CAPOX --> 25-30Gy/5 fraction RT (short course with optional boost).
Congrats @adapthyun & looking forward to study details. #ASTRO25
27 Sep 2025
NOM-ERA results just dropped! 🔥 #ASTRO25
Awesome work @adapthyun et al!
Wondering if those who got the optional 30 Gy × 5 primary tumor boost had larger tumors or more adverse features since cCR and TME-free survival looked similar overall.
sciencedirect.com/science/ar…
5
31
81
12,143
Hyun Kim retweeted
In addition to winning BEST PAPER submitted to RTT track for #ESTRO25 🎉 @RobAPRT will be presenting this work - May 5, 11:40am Vienna time
"APRT Analysis for Online Adaptive Radiotherapy Contouring and Adaptor Model Evaluations Using Time-Driven Activity-Based Costing" #radonc
5
5
18
1,106
Hyun Kim retweeted
24 Apr 2025
Congratulations to Stephanie Markovina, MD, PhD, a recipient of the 2025 Dean’s Impact Award! Her dedication to community-engaged leadership has created lasting impact across clinical care, #cervicalcancer research & mentoring trainees. Read more - bit.ly/42tSYtS
4
10
46
2,605
Hyun Kim retweeted
16 Apr 2025
Read this new brief report from @adapthyun @WashUMedRadOnc et al on minimizing bowel gas artifact in CT-guided online adaptive radiotherapy with prolonged supine positioning in the #RedJournal: tinyurl.com/redhkim
1
5
21
1,518
Hyun Kim retweeted
10 Apr 2025
Ablative RT for technically resectable (med inoperable) pancreas ca
In disease site w high rate distant mets, morbidity tradeoffs b/w local therapies must be considered
Small series, but ~early lung SBRT trials, potential for practice-changing paradigm
🤞future coop group RCT
10 Apr 2025
Ablative radiation therapy effectively controlled tumors and provided favorable 2-year survival rates in patients with resectable pancreatic cancer who could not undergo surgery.
ja.ma/4lxAyjx @EileenMOReilly @JohnCuaron
3
13
66
7,810
Hyun Kim retweeted
9 Apr 2025
Thanks for this paper!
Not too long ago, treating pancreas tumors w duodenal invasion to 100 Gy (prescription dose)/5 fx would have been unfathomable.
On NRG GI-011/LAP100, we will encourage 5 over 25 fx regimen - this paper suggests 5 fractions should be feasible for most.
8 Apr 2025
Congrats to @AldenDSouza3 @KylieKangMD for this work on MR guided adaptive SBRT for pancreatic tumors abutting/invading organs at risk in @IJROBP. Classic teaching is to prolong fractionation and avoid SBRT for OAR abutment/invasion due to toxicity. Still true in ART era? 1/
2
13
40
6,917
8 Apr 2025
Congrats to @AldenDSouza3 @KylieKangMD for this work on MR guided adaptive SBRT for pancreatic tumors abutting/invading organs at risk in @IJROBP. Classic teaching is to prolong fractionation and avoid SBRT for OAR abutment/invasion due to toxicity. Still true in ART era? 1/
2
19
53
10,787
8 Apr 2025
We quantify successful coverage by PTV_opt coverage since we are adapting each day. Mandate that PTV is covered by 25 Gy (otherwise TPS will push most of low dose away from OAR as well). Recognize that not everyone has access to adaptive radiation therapy... 3/
1
1
3
378
8 Apr 2025
However, if patient is medically inoperable or has locally advanced disease, consider MR guided ART. Potential to shorten to SBRT (5) fractionation for patient QOL and more time on systemic therapy if needed. 4/4 @WashUMedRadOnc
sciencedirect.com/science/ar…
2
335